AP-Brain Safety and Efficacy on Cognitive Performance Investigated in Healthy Middle-aged and Older Adults

Age-related cognitive decline, particularly affecting memory, is a growing concern, impacting quality of life and independence. Current interventions often have limited efficacy or significant side effects, leaving a substantial gap in safe and effective options for maintaining cognitive function. Many individuals experience self-reported memory problems before a formal diagnosis, highlighting a need for early, preventative, or supportive strategies. Investigating novel compounds like AP-Brain for their potential to support cognitive performance in healthy aging populations is crucial for addressing this unmet need.

This clinical trial is designed to investigate the safety and efficacy of AP-Brain across three distinct oral dosages in healthy middle-aged and older adults experiencing self-reported memory problems. Participants will be randomized to consume either AP-Brain 1 g, AP-Brain 3 g, AP-Brain 5 g, or a placebo. The primary endpoint will be changes in cognitive performance, assessed through memory assessment questionnaires. The study aims to compare the effects of each active dose against the placebo arm to determine dose-dependent impacts on memory and overall cognitive function, while also monitoring for any adverse events to establish a safety profile.

This record describes the design of an ongoing clinical trial, and as such, no results or findings are available at this time. The study is currently in the investigation phase, aiming to collect data on the safety and efficacy of AP-Brain at varying dosages. Therefore, there are no specific numbers, p-values, or fold-changes to report regarding cognitive performance or any other outcome. The main question regarding the effect of AP-Brain at 1 g, 3 g, and 5 g on cognitive performance remains to be answered upon completion of the trial and subsequent data analysis. > The trial's objective is to determine if AP-Brain can significantly impact cognitive performance compared to placebo in the target population.